Investment Thesis
Medifast is experiencing severe operational deterioration with revenue collapsing 36% YoY and the company posting negative operating and net income despite maintaining high gross margins of 68.1%. While the balance sheet remains fortress-like with zero debt and $71.5M in cash, the company is burning cash with negative free cash flow of -$836K and generating minimal operating cash flow, indicating fundamental business challenges that cannot be offset by balance sheet strength alone.
Strengths
- Fortress balance sheet with zero long-term debt and $71.5M cash reserves
- Exceptional liquidity with 4.8x current ratio and 4.3x quick ratio
- High gross margin of 68.1% demonstrates pricing power in core products
Risks
- Catastrophic 36% year-over-year revenue decline signals severe demand destruction
- Company is unprofitable with negative operating margin of -4.3% and net margin of -2.8%
- Negative free cash flow of -$836K despite $51.8M gross profit indicates operational dysfunction
- Minimal operating cash generation of only $260K suggests fundamental business model stress
- Return on equity and assets both deeply negative at -1.1% and -0.8% respectively
Key Metrics to Watch
- Quarterly revenue stabilization - continued monitoring of YoY revenue trends to assess demand recovery
- Path to operating profitability - when/if operating margin returns to positive territory
- Cash burn rate and runway - free cash flow trajectory and months of cash remaining at current burn rate
Financial Metrics
Revenue
76.0M
Net Income
-2.1M
EPS (Diluted)
$-0.19
Free Cash Flow
-836.0K
Total Assets
252.0M
Cash
71.5M
Profitability Ratios
Gross Margin
68.1%
Operating Margin
-4.3%
Net Margin
-2.8%
ROE
-1.1%
ROA
-0.8%
FCF Margin
-1.1%
Balance Sheet & Liquidity
Current Ratio
4.80x
Quick Ratio
4.30x
Debt/Equity
0.00x
Debt/Assets
21.6%
Interest Coverage
-274.58x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T12:27:36.220209 |
Data as of: 2026-03-31 |
Powered by Claude AI